Mylan Institutional LLC

I'll research this company before writing the profile.

Mylan Institutional LLC is a Delaware-organized limited liability company with its principal place of business at 4901 Hiawatha Drive, Rockford, Illinois (it has also listed a Morgantown, West Virginia address in regulatory filings). It is not independent: it is a wholly owned subsidiary within the group formerly headed by Mylan N.V. and, since November 16, 2020, by Viatris Inc. (NASDAQ: VTRS), formed when Mylan combined with Pfizer's Upjohn business. Viatris disclosed roughly 40 manufacturing sites and multi-billion-dollar annual revenue; Mylan's own 2018 10-K reported about 35,000 employees. Mylan Institutional does not report standalone financials, and no independent employee count is available.

The entity operates as a pharmaceutical supplier to the institutional market rather than to retail consumers. It sells specialty injectables (difficult-to-formulate products such as daptomycin for injection, haloperidol decanoate, octreotide acetate and levothyroxine sodium for injection) and unit-dose/unit-of-use oral solids in bar-coded, automation-ready packaging, primarily for hospital, group purchasing organization, wholesaler, long-term care and correctional customers. Its therapeutic emphasis is analgesics/anesthetics, anti-infectives, cardiology and oncology. The business took its current shape around 2010–2011 by combining Mylan's Bioniche Pharma specialty-injectable unit with UDL Laboratories' unit-dose packaging operation; it manufactures at a sterile injectables facility in Rockford, Illinois that has drawn FDA inspection observations.

Litigation posture: the structured data show one tracked matter and zero plaintiff-side filings — the profile of an operating company being sued, not a patent assertion entity. The sole tracked case, Helsinn Healthcare S.A. et al. v. Mylan Institutional LLC (D. Del., filed June 4, 2014), was a Hatch-Waxman ANDA dispute over generic palonosetron (Aloxi); Helsinn and Roche Palo Alto asserted five formulation patents. It was consolidated into lead case No. 13-688 and dismissed as to Mylan Institutional in October 2015.

This is Delaware pharmaceutical ANDA litigation, not the Eastern District of Texas NPE pattern. Related Helsinn palonosetron patents later reached the Supreme Court in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. (2019), which addressed the AIA on-sale bar.